mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection

S Rauch, K Gooch, Y Hall, FJ Salguero, MJ Dennis… - Biorxiv, 2020 - biorxiv.org
The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic
necessitates the fast development of vaccines to meet a worldwide need. mRNA-based
vaccines are the most promising technology for rapid and safe SARS-CoV-2 vaccine
development and production. We have designed CVnCoV, a lipid-nanoparticle (LNP)
encapsulated, sequence optimised mRNA-based SARS-CoV-2 vaccine that encodes for full
length, pre-fusion stabilised Spike protein. Unlike other mRNA-based approaches, CVnCoV …

[引用][C] mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection. bioRxiv. 2020: 2020.12. 23.424138

S Rauch, K Gooch, Y Hall, FJ Salguero, MJ Dennis… - DOI
以上显示的是最相近的搜索结果。 查看全部搜索结果